FDA approves Atelvia for osteoporosis

Warner Chilcott announced that the FDA has approved Atelvia (risedronate sodium delayed-release tablets) for the treatment of postmenopausal osteoporosis.

Atelvia, a bisphosphonate, is a delayed-release formulation of the currently marketed product, Actonel. Actonel is approved for the prevention and treatment of postmenopausal osteoporosis and glucocorticoid-induced osteoporosis (men & women), to increase bone mass in men with osteoporosis and the treatment of Paget's disease of bone.

Atelvia is expected to be available in early 2011


For more information call (800) 521-8813 or visit www.wcrx.com.